Although long-chain n3 polyunsaturated fatty acids [n3 PUFAs; eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)] have been reported to reduce platelet aggregation, the available evidence on this is equivocal. We previously demonstrated that the acute effects of n3 PUFA supplementation on platelet aggregation are sex specific. We aimed to determine if this gender bias is maintained during long-term n3 PUFA supplementation and whether this translates to other hemostatic markers. A double-blinded, randomized, placebo controlled trial was conducted in 94 healthy men and women.
Introduction
Fatty fish and marine oils that are rich sources of long-chain n3 PUFAs have sparked considerable interest in epidemiological and clinical studies, suggesting favorable effects for the prevention of atherosclerotic and thrombotic disease. The early observation that long-chain n3 PUFAs promote cardio-protection was first demonstrated in the 1970s by Dyerberg and Bang (1) in a series of prospective studies on Greenland Eskimos. These studies revealed that the rarity of ischemic heart disease and decreased thrombotic tendency in this population were linked to their consumption of a seafood diet high in the n3 PUFAs EPA and DHA.
The formation of occlusive thrombi resulting in cardiovascular complications is generally a platelet-dependent phenomenon. This process is initiated when platelets adhere to subendothelial structures of injured blood vessels, release vasoactive substances, and aggregate, resulting in the formation of platelet-rich thrombi. These sequential primary hemostatic events are dependent and mediated by an interplay of cellular adhesion molecules and proteins such a P-selectin (P-sel) and von Willebrand factor (vWF), proaggregatory factors including thromboxane (TX) 5 A 2 , and coagulation factors of secondary hemostasis (2) . Inhibition of these procoagulant elements can facilitate thrombus dissolution via the fibrinolytic system (3). Subsequently, degradation of the fibrin clot also plays a pivotal role in the control of thrombus development, and abnormally elevated concentrations of the fibrinolysis inhibitor, plasminogen activator inhibitor-1 (PAI-1), have been associated with some instances of thrombotic disease (4) .
Long-chain n3 PUFAs provide a remarkable contribution to the physical properties of biological membranes and the ability to modulate the activity of membrane-associated proteins (5) . In addition, the incorporation of n3 PUFAs in cell membranes modifies eicosanoid production (6) . However, the inverse relationship between n3 PUFA intake and platelet aggregation has not been a consistent finding. Whereas some dietary intervention studies have reported that n3 PUFA supplementation reduces formation of TXA 2 (7) (8) (9) , prolongs bleeding time (10) , reduces platelet count (11) , and is inversely associated with expression of cellular adhesion molecules and plasma concentrations of several coagulation factors (12) , other studies have yielded equivocal evidence for their effectiveness against these biomarkers of hemostasis (13) (14) (15) (16) (17) (18) (19) . Disparate findings concerning the effects of n3 PUFAs on platelet function may be explained by sexdependent differences in platelet aggregation in response to EPA or DHA. Despite the fact that fish and fish oils contain EPA and DHA in variable amounts, few well-designed studies in humans have assessed their individual effects. In the available fish oil and platelet aggregation literature, a wide variability in terms of dosages and concentration ratios of EPA:DHA is apparent. This variable, coupled with the nonmodifiable factor of gender, may likely explain the inconsistent results in the fish oil and platelet aggregation literature. Furthermore, the majority of these hemostatic markers have been reported to be correlated or influenced by sex hormone levels (20) (21) (22) , which in turn influence n3 PUFA uptake and metabolism (23, 24) . Indeed, we previously demonstrated the existence of sex-dependent platelet responses with individual, long-chain n3 PUFAs both in vitro (25) and in vivo after short-term exposures (26, 27) . The aim of the present investigation was thus to extend our findings to determine whether these sex-specific platelet responses are maintained with chronic, long-chain n3 PUFA supplementation and further examine their effects on hemostatic markers. More specifically, we aimed to examine the sex-dependent effects of 4 wk of supplementation with EPA-rich compared with DHA-rich oils on ex vivo platelet aggregation and plasma concentrations of TXB 2 (the inactive metabolite of TXA 2 that serves as a surrogate marker), P-sel, PAI-1, and vWF activity in healthy men and women.
Participants and Methods
Participants. This study was a randomized, double-blinded, placebocontrolled intervention trial. A total of 94 healthy participants completed the study, 41 men and 53 women, recruited from the general community of Newcastle, NSW, Australia from June 2010 to May 2011. Exclusion criteria were: diagnosed noninsulin-dependent diabetes; insulin resistance; impaired glucose tolerance; cardiovascular or hematological disorders; BMI >35 kg/m 2 ; and taking aspirin, antiplatelet medication, or nonsteroidal antiinflammatory drugs. Participants were also excluded if they previously consumed fish oil supplements or regularly consumed >2 seafood servings/wk. Participants were asked to complete a medical questionnaire and 24-h food recall and follow a diet low in tomatoes and seafood prior to the study day and during the intervention. All participants provided written informed consent according to governmental regulations concerning the ethical use of human volunteers. Approval for the study was granted by the Human Research Ethics Committee of the University of Newcastle, Australia. All work was conducted in the research unit at the Medical Sciences Building, University of Newcastle. All participants attended the research unit on 2 occasions. On the first visit participants completed a pretrial medical history questionnaire and a 24-h food record prior to a fasting blood sample donation.
Using computer-generated methods, participants were block randomized with sex stratification to a treatment protocol of 2 3 1-g capsules/d for 4 wk of supplements containing either: 1) placebo (Sunola oil); 2) EPA-rich oil supplement [500:100 mg EPA:DHA (EPAX 5510 TG/N]; or 3) DHA-rich oil supplement [100:500 mg EPA:DHA (EPAX 1050 TG/N)].
All participants and the co-investigators responsible for treatment allocation and assessment were unaware of the treatment groups. The supplements were masked and identifiable only by code to which only the principal study investigator had access. Participants returned immediately after the intervention for a final fasting blood donation. Compliance with the instructions and supplement intake was monitored via pre-and postintervention capsule count-back, telephone communication, analysis of plasma fatty acid composition, and analysis of the daily record of capsule intake documented by participants.
Blood analysis. From each participant, venous blood was collected using a 21-gauge needle into Vacutainer tubes containing 3.2% sodium citrate, EDTA, or lithium heparin following a >10-h fast. All samples were collected by the same venipucturist from the antecubital vein. Whole citrate blood was analyzed 20 min after collection for platelet aggregation assays. For measurement of TXB 2 , P-sel, PAI-1, and plasma fatty acid composition, EDTA blood was centrifuged at 3000 3 g for 10 min to obtain platelet-free plasma and aliquots were stored at 280°C until further analysis. For measurement of vWF activity, sodium citrate blood was centrifuged and stored as above. Blood collected into the EDTA tubes was used for analysis of a full blood count using a Coulter LH780 blood analyzer. The lithium heparin tubes were used to measure hormonal levels (testosterone, estradiol), analyzed by the Hunter New England Area Health Pathology Services (NSW, Australia), using standard ELISA assays on an automated analyzer (ES700, Roche Diagnostics).
Platelet aggregation assays. Platelet aggregation and lag time (time taken to initiate aggregation) was measured using a Chronolog 560ca whole-blood aggregometer (Chronolog-Log) according to the method of Cardinal and Flower (28) . Whole blood (500 mL) was diluted with an equal volume of PBS. Samples were pre-incubated for 6 min at 37°C prior to stimulation with collagen (5 mg/mL). Platelet aggregation was measured as the change in impedance (ohms) produced 6 min after the addition of collagen and the area under the aggregation curve was calculated. Measurement variation was minimized by having the same trained technician process all samples using the same equipment.
Measurement of TXB 2 , vWF activity, P-sel, and PAI-1. All plasma biomarkers were measured using commercially available immunoassay kits following the manufacturerÕs instructions. TXB 2 was quantitated using a competitive enzyme immunoassay (Sapphire Bioscience) and soluble P-selectin and PAI-1 concentrations were measured by sandwich ELISA (R &D Systems) Detection of vWF activity was determined using a collagen binding assay (Life Therapeutics), where results were reported as percent (%) of normal relative to the standard curve of the known concentrations of normal plasma. All samples were analyzed in duplicate and only those with a CV <15% were used in the final analysis. Replicate samples from individual participants were determined in the same series to avoid bias due to assay variability.
Plasma fatty acid analyses. The fatty acid composition of plasma lipids was determined according to a modification in the method of Lepage and Roy (29) using an acetyl chloride methylation procedure.
FAMEs were quantified using GC (Hewlett Packard 6890). The identity of each fatty acid peak was ascertained by comparison of the peaksÕ retention time with those of synthetic standards of known fatty acid composition (Nu Check Prep). The relative amount of each fatty acid was quantified by integrating the area under the peak and dividing the result by the total area for all fatty acids. The fatty acid results were reported as the percentage of total fatty acids.
Statistical analysis. Data calculations, sample size, and statistical analyses were performed using the IBM Statistics software (version 20, SPSS). A sample size of 28 was calculated using means, SD, and power calculations from our previous data for comparison of platelet aggregation between men and women using a 2-tailed t test, an a of 0.05, and a power of 0.90. Based on this data, the study was powered to detect a minimum 10% change in platelet aggregation and allowed for a 10% dropout rate due for unforeseen circumstances. Therefore, a total sample size of 90 (n = 90; 30/supplement group) was recruited, including any dropouts. All data are presented as mean 6 SEM. Changes in hemostatic markers, platelet aggregation, and plasma fatty acids were determined by calculating the difference from blood samples collected at 4 wk postintervention with baseline values and expressed as a percentage change. Preliminary assumption testing using the Kolmogorov-Smirnov tests for normality and stem and leaf plot showed that all data were normally distributed. The test for outliers and homogeneity of variance showed that there were no serious violations observed for all test variables within sex and n3 PUFA group. Significance was assessed using 1-way between-groups ANOVA and the repeated-measures t test for paired data. Comparisons between sex and different n3 PUFA groups were made with general linear models using 2-way univariate and multivariate ANOVA with post hoc Tukey tests. Bivariate correlations were Pearson product moment coefficients. P < 0.05 was adopted throughout to determine significance unless otherwise stated.
Results
Baseline demographics. The mean 6 SEM participant age was 39.6 6 1.7 y without significant age differences between the male and female cohorts. Approximately 70% of the female cohort was of premenopausal status and female participants in the study had significantly higher platelet count, higher concentrations of estradiol, and significantly greater baseline platelet aggregation than males. Males had significantly greater BMI (kg/ m 2 ), higher hematocrit and RBC count, longer lag time (s), and higher plasma testosterone and EPA concentrations ( Table 1) . There were no significant differences in these measures between the men in each treatment group or the women in each group. No baseline differences were observed with subgroup analyses for sex within and between treatment groups for platelet aggregation biomarkers. In the EPA group, there were 31 participants (M:F = 13:18); in the DHA group, there were 31 (M:F = 15:16) and in the placebo group, there were 32 participants (M:F = 15:17). There were no losses to follow-up or exclusions during each phase of the study.
Relationship among plasma hormone concentrations, platelet aggregation, and plasma fatty acids prior to supplementation. Significant correlations between sex and hemostatic variables were observed at baseline. Hematocrit and RBC count were positively associated with testosterone concentrations (P < 0.001 and P < 0.001, respectively) but negatively associated with estradiol concentrations (P < 0.001 and P < 0.001, respectively). Baseline aggregation was positively associated with platelet count (P < 0.001) but inversely related to lag time (P < 0.001) and testosterone concentrations (P = 0.03). Accordingly, testosterone concentrations were negatively associated with platelet count (P = 0.003) but positively associated with lag time, indicating delayed time to aggregation. The only plasma fatty acid to show any association was baseline plasma EPA, which was positively correlated with testosterone (P = 0.03) ( Table 2 ).
Effects of supplementation on platelet aggregation. When the entire cohort was considered, 4 wk of supplementation with either EPA-or DHA-rich oils effectively reduced platelet aggregation compared with placebo by 211.8 6 2.7% (P = 0.02) and 214.8 6 2.2% (P = 0.001), respectively (Fig. 1) . As further depicted in Figure 1 , when stratified by sex, the aggregation response pattern was divided between the men and women, and a sex 3 treatment effect was observed (P = 0.001). Furthermore, subgroup with post-hoc analyses showed that in males, the EPA-rich treatment effectively reduced platelet aggregation by 218.4 6 3.2% compared with a reduction of only 22.7 6 2.8% in the men taking placebo and 25.5 6 3.1% in women taking the same EPA supplement (P = 0.01). In contrast, in women, the DHArich treatment decreased platelet aggregation with a 218.9 6 2.9% overall reduction compared with only 22.1 6 2.9% in the women taking placebo (P = 0.001) and 29.0 6 3.5% in the males consuming the same DHA supplement (P = 0.02) (Fig. 1) .
These results were corroborated by analysis of associations with hormone concentrations: testosterone concentrations were inversely related to platelet aggregation activity after EPA supple- mentation (P = 0.04) but positively associated after DHA supplementation (P = 0.02) ( Table 2 ). Furthermore, testosterone concentrations were inversely correlated with plasma DHA concentrations post-DHA supplementation (P = 0.05) ( Table 2 ).
Markers of platelet activity and aggregation. When analyzed by treatment group only, plasma TXB 2 , vWF activity, and P-sel and PAI-1 concentrations did not significantly change compared with placebo ( Table 3) . When further stratified by sex, an effect was observed only in PAI-1 concentrations after supplementation with EPA in men compared with women (P = 0.05) ( Table 4) . No other effects were observed within subject or between treatment groups.
Plasma fatty acid composition. Plasma fatty acid compositions were measured to ensure participant compliance in each treatment group. Plasma EPA concentrations significantly increased in both EPA and DHA supplementation groups but not in the placebo group. Similarly, plasma DHA concentrations also significantly increased in both supplementation groups and not in the placebo group. In contrast, plasma arachidonic acid (AA) concentrations were not significantly altered in any of the supplementation groups or with placebo (Table 3) .
Using the multivariate ANOVA general linear model, a significant sex 3 treatment effect was observed in the DHA supplementation group between men and women (P = 0.006). Although plasma EPA concentrations significantly increased to an equal extent in men and women supplemented with EPA ( Fig.  2A) , plasma DHA concentrations increased significantly more in women (148 6 25.1%) compared with men (84.5 6 18.7%) in the DHA supplementation group (P = 0.03) (Fig. 2B) . No significant changes in plasma EPA, DHA, or AA were observed in the placebo group between or within treatment groups.
Discussion
Several uncontrolled studies have reported conflicting results regarding the effects of fish oil supplementation on platelet aggregation (13-18); thus, its putative effects remain unclear and controversial. We report for the first time to our knowledge in a controlled study that the antiaggregatory effects of EPA and DHA are sex specific. Here, we offer a plausible explanation whereby sex, a nonmodifiable determinant of cardiovascular disease, may likely explain the inconsistent results in the fish oil and platelet aggregation literature.
In the present study, we have shown that sex-specific responses exist in platelet aggregation following 4 wk of dietary TABLE 2 Correlations between plasma hormone concentrations and platelet aggregatory response in men and women at baseline or after 4 wk of EPA or DHA supplementation supplementation with EPA-or DHA-rich oil capsules. These data confirm our previous findings of sex-dependent platelet responses in vitro (25) and ex vivo in an acute supplementation study (26, 27) , therefore extending our finding that these sexdependent, antiaggregatory effects of n3 PUFAs are maintained over longer terms. Consistent with our earlier findings, EPA-or DHA-rich oils were equally effective in reducing platelet aggregation following a 4-wk supplementation period when the entire cohort was considered. With sex subgroup analysis, we demonstrated a significant interaction between sex and treatment; the antiaggregatory effects of EPA and DHA were clearly segregated into the male and female groups. It was evident that the effects of EPA were specific in reducing platelet aggregation in men, with a marked 218.4% reduction, whereas no effects were observed in the female cohort. Conversely, the effects of DHA were unique to women to a similar 218.9% decrease in platelet aggregability and without effect in men. This may explain the lack of effect of DHA supplementation on platelet aggregation in previously published studies conducted predominantly or exclusively in men (13, 15, 30) . Administration of testosterone has been shown to decrease plasma DHA concentrations (31) and to increase platelet TXA 2 receptor density and aggregation responses in healthy males (32) . The lack of effect observed in men with DHA supplementation in our study may be owing to the sex differences in n3 PUFA metabolism whereby men synthesize and/or retain less DHA compared with women. Sex differences in n3 PUFA metabolism have been well established; women of child-bearing age have been shown to have higher concentrations of plasma DHA and lower concentrations of EPA than men, and the difference is independent of dietary intake (33) . This was further supported by Giltay et al. (31) , who observed an increase in DHA status with estrogen administration but a decrease with testosterone. This is in line with our findings where plasma DHA concentrations increased to a greater extent in women than in men (148 vs. 64%, respectively) following supplementation with DHA-rich capsules, demonstrating a significant sex 3 treatment interaction (P = 0.006). Considering that plasma fatty acid composition following chronic n3 PUFA supplementation reflects that of platelets (34) , our data are consistent with the previously published in vitro study showing slower movement of DHA into platelet phospholipids in men (35) . Furthermore, testosterone concentrations were inversely correlated with plasma DHA concentrations post-DHA supplementation. This is also consistent with the previous observations that testosterone administration reduces DHA concentrations (31) and increases platelet aggregation responses in healthy men (32) . This suggests that higher testosterone concentrations may regulate the retention (reduced uptake and/or increased oxidation) of DHA from the supplement, resulting in only limited inhibition of platelet aggregation in the men within our study. In further support of this, we observed a positive relationship between platelet aggregation at 4 wk following DHA supplementation with testosterone concentrations. In contrast, higher concentrations of testosterone were associated with lower platelet aggregation activity following EPA supplementation.
Similar to reported studies of 4-6 wk of supplementation (30, 36) , TXB 2 concentrations in our study participants were not altered by EPA or DHA supplementation. It is likely that a longer supplementation period or higher doses are required to alter eicosanoid production.
EPA and/or DHA supplementation is known to partially replace AA from the platelet phospholipids to compete as a substrate for the cyclooxygenase enzyme, resulting in reduced conversion toTXA 2. TXA 3 derived from EPA is biologically less active compared with TXA 2 , thereby reducing platelet activity (6) . Nonetheless, platelet aggregation was significantly reduced regardless of TXB 2 concentrations in our study. Coincidently, no changes in plasma AA concentrations were evident, whereas the EPA or DHA concentrations increased following dietary supplementation, confirming both compliance with supplementation and no change in n6 PUFA dietary intake. It is likely that mechanisms other than eicosanoid production are responsible for the observed changes in platelet aggregation. Previous studies also reported no change in TXA 2 concentrations yet reduced platelet aggregation even with high doses of DHA (37) or EPA (9) .
Alternative mechanisms of action have been proposed, including effects on platelet adhesion and platelet/endothelial cell activation (38) . P-sel and vWF are glycoproteins expressed on activated platelets. P-sel supports the recruitment of leukocytes Sex-specific platelet responses to fish oil 461
and platelet adhesion (39) , and vWF mediates platelet aggregation by binding platelets to collagen in the exposed endothelium (40); their inhibition has been shown to enhance thrombus dissolution (3) . In the present study, no effects were observed on these hemostatic markers with EPA-or DHA-rich oil supplementation. It may be possible that higher doses may be required to influence these markers. Additionally, a study by Eschen et al. (21) reported that the effects of n3 PUFA on cellular adhesion molecules may be dependent on sex and n3 PUFA dose. Fibrinolysis, the final stage in hemostasis, has been considered a target treatment approach to enhance dissolution of the thrombus commonly through its effects on plasminogen (41) . The degradation or the inhibition of fibrinolysis is tightly regulated by the interface between the plasminogen activators (PAs) and PAIs, respectively (42) . The PAI-1 enzyme is the dominant PAI in the circulation, representing 60% of plasminogen activation inhibition in plasma. Subsequently, high concentrations of PAI-1 lead to a reduction in plasmin degradation of fibrinpromoting thrombosis (43) . Conflicting results have been reported on the influence of fish oil on PAI-1 concentrations, some reporting impaired fibrinolytic capacity (44) whereas others find improvements (45) or without effect (46) . Interestingly, we observed a significant difference in PAI-1 concentrations between the male and female groups following EPA supplementation. The PAI-1 concentration decreased by a modest 25.3% in men, whereas in women, it increased 1.9%. Environmental and genetic influences have been proposed with polymorphism of the PAI-1 gene, in particular the 4G allele, where correlations between PAI-1 and TG concentrations have been reported (47) . In addition, a large intra-and interpersonal variability in plasma PAI-1 activity coupled with diurnal variation has been reported (48) along with the influence of sex hormones upon PAI-1 synthesis (49, 50) . Although our study was not adequately powered, the changes in biomarkers of platelet adhesion and fibrinolysis were consistent with the sex-specific trend and collectively prompt further investigations. These observations also suggest that changes in ex vivo platelet aggregation do not necessarily correspond to changes in variables of primary hemostasis (platelet activation, adhesion). The sex-specific inhibitory effects on platelet aggregation observed with EPA and DHA could be via coagulation factors of secondary hemostasis, which we anticipate to explore further.
In a recent study, the association among the baseline values of platelet aggregation, sex, and hematological variables were reported (51), which was consistent with our findings. Others have also reported that sex hormone level is the confounding variable for these platelet differences observed (52, 53) . Furthermore, it is interesting to note that sex-specific effects have been reported with the antiplatelet action of aspirin use where it does not appear to be beneficial to women compared with men (54) . In the NurseÕs Health Study cohort, when stratified by aspirin use, n3 PUFA intakes were inversely associated with risk of thrombotic infarction, primarily among women who were not regular aspirin users (55) . A comparison between these studies and that reported here would be helpful in advancing the understanding of the sex-specific effects observed for thrombotic disease risk.
In our present study, we demonstrated a significant sex 3 treatment interaction on platelet aggregation, PAI-1 concentrations and on plasma n3 PUFA uptake and furthermore established sex-specific associations between sex hormonal concentrations and platelet aggregation with their respective treatments. The significant interactions between sex and specific supplemental long-chain n3 PUFA result in platelet aggregation being differentially affected in men and women. In attempts to resolve the existing controversy, our findings suggest effects of EPA and DHA on platelet aggregation their effects are not shared or complementary, rather they are sex-specific. We have shown that these sex-specific, antithrombotic effects are extended to the fibrinolytic system with the reduction of PAI-1 concentrations. These findings provide insight into the intricate mechanism whereby EPA and DHA exert their effects. In addition, these novel findings allow for optimal cardio-protection that is tailored for both gender groups and offers a safe and nonpharmacological approach. With respect to thrombotic disease risk, men would likely benefit more from supplementation with EPA, whereas women are more responsive to DHA.
